Sensei Biotherapeutics, Inc.
News
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
Globe Newswire BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...\n more…
Sensei Biotherapeutics to Present at Upcoming Conferences
Globe Newswire BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...\n more…
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 0.7%
Ticker Report Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report)'s share price fell 0.7% during trading on Monday . The company traded as low as $0.58 and last traded at $0.61. 23,400 shares traded hands...\n more…
HC Wainwright Brokers Boost Earnings Estimates for Sensei Biotherapeutics, Inc. (NASDAQ:SNSE)
Ticker Report Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Free Report) - HC Wainwright boosted their Q3 2024 earnings per share (EPS) estimates for Sensei Biotherapeutics in a report issued on Wednesday, August...\n more…
SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSNSE stock results show that Sensei Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Sensei Biotherapeutics GAAP EPS of -$0.28
SeekingAlpha.com: All News no summary\n more…